PTT 3196
Alternative Names: PTT-3196Latest Information Update: 18 Apr 2022
At a glance
- Originator Pathios Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action GPR65 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Apr 2022 Pharmacodynamics data from preclinical studies in cancer presented at 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 07 Jul 2021 Preclinical trials in Cancer in United Kingdom (PO) prior to July 2021
- 07 Jul 2021 Pharmacodynamics data from preclinical studies in cancer released by Pathios Therapeutics